Jinwan Wang

5.6k total citations · 2 hit papers
90 papers, 2.7k citations indexed

About

Jinwan Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jinwan Wang has authored 90 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 53 papers in Oncology and 22 papers in Surgery. Recurrent topics in Jinwan Wang's work include Gastric Cancer Management and Outcomes (24 papers), Colorectal Cancer Treatments and Studies (22 papers) and Renal cell carcinoma treatment (18 papers). Jinwan Wang is often cited by papers focused on Gastric Cancer Management and Outcomes (24 papers), Colorectal Cancer Treatments and Studies (22 papers) and Renal cell carcinoma treatment (18 papers). Jinwan Wang collaborates with scholars based in China, United States and Japan. Jinwan Wang's co-authors include Wentao Mao, Yihebali Chi, Yongkun Sun, Feng Du, Ling He, Hao Yu, Rui‐Hua Xu, Jianming Xu, Chunxia Du and Shuting Li and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jinwan Wang

86 papers receiving 2.7k citations

Hit Papers

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the ... 2014 2026 2018 2022 2014 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
    2014 474 citations Rui‐Hua Xu, Jianming Xu et al. profile →
  2. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
    2016 332 citations Yongkun Sun, Feng Du et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jinwan Wang China 21 1.5k 1.4k 552 530 296 90 2.7k
Weihan Zhang China 25 558 0.4× 1.1k 0.8× 758 1.4× 337 0.6× 369 1.2× 159 2.3k
Dorothea Wagner Germany 28 1.8k 1.2× 2.2k 1.6× 1.2k 2.3× 794 1.5× 680 2.3× 152 4.4k
Fumio Nagashima Japan 27 1.6k 1.1× 1.1k 0.8× 734 1.3× 754 1.4× 168 0.6× 148 2.9k
Răzvan Cristescu United States 31 1.8k 1.2× 1.0k 0.7× 363 0.7× 605 1.1× 89 0.3× 107 3.6k
Wooil Kwon South Korea 30 2.4k 1.6× 1.4k 1.0× 2.0k 3.5× 228 0.4× 109 0.4× 213 3.5k
Hideki Fujii Japan 44 2.3k 1.5× 1.0k 0.8× 1.4k 2.5× 1.5k 2.9× 113 0.4× 180 6.3k
Tae‐Yop Kim South Korea 24 470 0.3× 363 0.3× 464 0.8× 396 0.7× 75 0.3× 129 2.2k
Atsushi Arakawa Japan 27 830 0.6× 696 0.5× 586 1.1× 683 1.3× 74 0.3× 179 2.7k
Liying Zhao China 29 1.0k 0.7× 1.0k 0.7× 658 1.2× 1.1k 2.1× 174 0.6× 120 3.0k
Masayoshi Yasui Japan 25 816 0.5× 628 0.5× 865 1.6× 425 0.8× 165 0.6× 190 2.2k

Countries citing papers authored by Jinwan Wang

Since Specialization
Citations

This map shows the geographic impact of Jinwan Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinwan Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinwan Wang more than expected).

Fields of papers citing papers by Jinwan Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinwan Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinwan Wang. The network helps show where Jinwan Wang may publish in the future.

Co-authorship network of co-authors of Jinwan Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Jinwan Wang. A scholar is included among the top collaborators of Jinwan Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinwan Wang. Jinwan Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chi, Yihebali, Jing Zhang, Yang Yang, et al.. (2021). Efficacy and safety of anlotinib in patients with advanced malignancy: a single-center, single-arm, phase 2 trial. International Journal of Clinical Oncology. 26(9). 1611–1618. 3 indexed citations
2.
Si, Xiaoyan, Jinwan Wang, Ying Cheng, et al.. (2020). A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 12. 3863580889–3863580889. 11 indexed citations
3.
4.
Chi, Yihebali, Zhiwei Fang, Xiaonan Hong, et al.. (2018). Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clinical Cancer Research. 24(21). 5233–5238. 245 indexed citations
5.
6.
Cui, Chengxu, Lifang Yuan, Jinwan Wang, et al.. (2016). Advanced duodenal carcinoma: Chemotherapy efficacy and analysis of prognostic factors. Oncology and Translational Medicine. 2(1). 16–20.
7.
Song, Yan, Chunxia Du, Wen Zhang, et al.. (2016). Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy. Chinese Medical Journal. 129(5). 530–535. 7 indexed citations
8.
Du, Feng, Susheng Shi, Yongkun Sun, Jinwan Wang, & Yihebali Chi. (2015). Clinicopathological Characteristics and Prognosis of Colorectal Cancer in Chinese Adolescent Patients. Chinese Medical Journal. 128(23). 3149–3152. 6 indexed citations
9.
Chi, Yihebali, Shugeng Gao, Feng Du, et al.. (2015). Diagnosis, treatment, and prognosis of bronchopulmonary carcinoid. Anti-Cancer Drugs. 27(1). 54–59. 4 indexed citations
10.
11.
Du, Chunxia, Ruoxi Hong, Yuehua Liu, et al.. (2014). Scalp metastasis from gastric cancer: A case report and literature review. Oncology Letters. 9(2). 641–644. 4 indexed citations
12.
Chi, Yihebali, Feng Du, Hong Zhao, Jinwan Wang, & Jianqiang Cai. (2014). Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors. World Journal of Gastroenterology. 20(43). 16252–16252. 21 indexed citations
13.
Chi, Yihebali, Hao Yu, Zhenzhong Wang, et al.. (2013). An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chinese Medical Journal. 126(9). 1642–1646. 88 indexed citations
14.
Du, Chunxia, Ruoxi Hong, Yuankai Shi, Xiaoduo Yu, & Jinwan Wang. (2013). Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients. Journal of Neuro-Oncology. 115(2). 285–291. 19 indexed citations
15.
Yang, Lin, Qiong Qin, Aiping Zhou, et al.. (2013). Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer. Molecular and Clinical Oncology. 2(1). 93–98. 5 indexed citations
16.
Huang, Jing, Yi Zhou, Xinming Zhao, et al.. (2012). Primary small cell carcinoma of the stomach: An experience of two decades (1990–2011) in a Chinese cancer institute. Journal of Surgical Oncology. 106(8). 994–998. 14 indexed citations
17.
Song, Yan, et al.. (2010). Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma. Chinese Journal of Cancer. 29(1). 71–75. 16 indexed citations
18.
Zhou, Aiping, et al.. (2009). Clinical study of sorafenib in the treatment of Chinese patients with metastatic renal cell carcinoma. Zhonghua miniao waike zazhi. 30(1). 10–14. 1 indexed citations
19.
Wang, Jinwan. (2007). PhaseIhuman tolerability trial of gambogic acid. Zhongguo xin yao zazhi. 19 indexed citations
20.
Ding, Li, Di Huang, Jinwan Wang, & Shuting Li. (2006). Determination of gambogic acid in human plasma by liquid chromatography-atmospheric pressure chemical ionization–mass spectrometry. Journal of Chromatography B. 846(1-2). 112–118. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weihan Zhang Breakdown of academic impact, for papers by Dorothea Wagner Breakdown of academic impact, for papers by Fumio Nagashima Breakdown of academic impact, for papers by Răzvan Cristescu Breakdown of academic impact, for papers by Wooil Kwon Breakdown of academic impact, for papers by Hideki Fujii Breakdown of academic impact, for papers by Tae‐Yop Kim Breakdown of academic impact, for papers by Atsushi Arakawa Breakdown of academic impact, for papers by Liying Zhao Breakdown of academic impact, for papers by Masayoshi Yasui
Rankless by CCL
2026